Measuring Surgical Recovery After Radical Cystectomy
NCT03193970
Recruiting
The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed baseline of multiple patient-reported outcomes (PRO) and clinician-reported outcomes (CRO) as well as various presenting conditions associated with them, so that future quality improvement interventions can be evaluated accurately as to their relative contribut... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of California - San Francisco, San Francisco, California +10 locations
Conditions: Bladder Cancer
Register for Updates
Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy
NCT03434080
Recruiting
Background: New ways to study the brain as people move include near-infrared spectroscopy (NIRS) and electroencephalography (EEG). NIRS uses laser light shone through the scalp to look at blood flow in the brain which increases with movement. EEG records electrical activity in the brain. Little is known about brain activity while children learn new motor skills. Researchers want to learn more about how small children with and without cerebral palsy use their brain to control their body. This ma... Read More
Gender:
ALL
Ages:
Between 3 months and 5 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Autism, Cerebral Palsy
Register for Updates
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
NCT03830229
Recruiting
Background: -A gene provides instructions to the body. Mutated genes can sometimes cause cancer. Germline mutations are those people are born with. These mutations in the BAP1 gene can cause mesothelioma and other cancers. Researchers want to study people with germline mutations of BAP1 and other genes known to cause cancer. Objective: -To learn how cancer might develop in people with certain gene mutations. Eligibility: -People ages 2 and older with a germline mutation in BAP1 or another g... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mesothelioma, Families
Register for Updates
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
NCT04204941
Recruiting
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +20 locations
Conditions: Advanced Epithelioid Sarcoma, Advanced Soft-tissue Sarcoma
Register for Updates
Targeted TDCS to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia.
NCT04432883
Recruiting
62 patients who are one year post stroke and have Aphasia as a result of that stroke will be recruited. Participants will have 4 assessment sessions and 15 treatment sessions. The TDCS will be to right Inferior Frontal Gyrus (IFG) (25 active, 25 sham) for 15 days. A combined semantic feature analysis/phonological components analysis treatment will be paired with the stimulation. Two assessment sessions will be pretreatment, 1 session immediately post-treatment, and 1 session at 3 months follow-u... Read More
Gender:
ALL
Ages:
Between 25 years and 85 years
Trial Updated:
04/30/2025
Locations: University of New Mexico Center for Brain Recovery and Repair, Albuquerque, New Mexico
Conditions: Stroke, Aphasia
Register for Updates
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
NCT04750928
Recruiting
Background: NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from nerves, can cause serious medical problems. The only treatment is surgery. Researchers want to see if a drug called abemaciclib can help. Objective: To find a safe, tolerable dose of abemaciclib for treating atypical neurofibromas. Eligibility: People ages 12 and older who have NF1 and have one or more atypical neurofibromas that cannot or will not be removed with surgery D... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neurofibromatosis 1
Register for Updates
Tobramycin Injection to Prevent Infection in Open Fractures
NCT04964947
Recruiting
The goal of open extremity fracture (OEF) treatment is to promote fracture healing and restore function while preventing the development of infection. This is achieved through systematic and timely wound debridement and irrigation, fracture stabilization, tetanus prophylaxis, systemic and local antimicrobial therapy, and judicious timing of wound closure based on cleanliness. Early prophylactic systemic antibiotics lower infection rates in open fractures but have limitations of achieving adequat... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: University of Kentucky, Lexington, Kentucky +2 locations
Conditions: Wound Infection, Fractures, Open, Surgical Site Infection
Register for Updates
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
NCT05213598
Recruiting
Background: In Fontan Associated Liver Disease (FALD), congestion of blood in the liver causes cirrhosis. This condition can cause death. Researchers want to understand what triggers this process and find new treatments for it. Objective: To understand how long-term congestion of blood in the liver causes liver scarring that eventually leads to cirrhosis. Eligibility: People aged 18 and older who are at risk of developing FALD from the Fontan procedure. Design: Participants will be screen... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Congenital Heart Disease
Register for Updates
Characterization of Nociception Phenotype in Individuals With Intellectual Disability
NCT05473429
Recruiting
Background: People with intellectual disability (ID) often have physical disabilities as well. These physical problems can affect their bones, muscles, nerves, and gastrointestinal tracts. All of these issues can also cause pain. Yet little research has been done on pain in people with ID. Objective: To compare brain responses to unpleasant stimuli in people with and without ID. Eligibility: People aged 8 to 30 years diagnosed with an ID. Healthy volunteers without an ID are also needed. D... Read More
Gender:
ALL
Ages:
Between 8 years and 30 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Intellectual Disability
Register for Updates
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
04/30/2025
Locations: AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona +334 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
SYMPHONY-PE Study for Treatment of Pulmonary Embolism
NCT06062329
Recruiting
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: Huntsville Hospital, Huntsville, Alabama +18 locations
Conditions: Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Register for Updates
Evaluate the Neurological Effects of EryDex on Subjects With A-T
NCT06193200
Recruiting
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
04/30/2025
Locations: University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California +20 locations
Conditions: Ataxia Telangiectasia
Register for Updates